WO2006102395A3 - Delivery systems and methods for diagnosing and treating cardiovascular diseases - Google Patents
Delivery systems and methods for diagnosing and treating cardiovascular diseases Download PDFInfo
- Publication number
- WO2006102395A3 WO2006102395A3 PCT/US2006/010371 US2006010371W WO2006102395A3 WO 2006102395 A3 WO2006102395 A3 WO 2006102395A3 US 2006010371 W US2006010371 W US 2006010371W WO 2006102395 A3 WO2006102395 A3 WO 2006102395A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- relates
- diagnosing
- methods
- delivery systems
- cardiovascular diseases
- Prior art date
Links
- 208000024172 Cardiovascular disease Diseases 0.000 title 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 abstract 2
- 229950004354 phosphorylcholine Drugs 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/221—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by the targeting agent or modifying agent linked to the acoustically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06739249A EP1866416A2 (en) | 2005-03-22 | 2006-03-22 | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
JP2008503125A JP2008534508A (en) | 2005-03-22 | 2006-03-22 | Delivery system and method for diagnosing and treating cardiovascular disease |
CA002602946A CA2602946A1 (en) | 2005-03-22 | 2006-03-22 | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
AU2006227133A AU2006227133A1 (en) | 2005-03-22 | 2006-03-22 | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66430005P | 2005-03-22 | 2005-03-22 | |
US60/664,300 | 2005-03-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006102395A2 WO2006102395A2 (en) | 2006-09-28 |
WO2006102395A3 true WO2006102395A3 (en) | 2007-05-10 |
Family
ID=36930417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/010371 WO2006102395A2 (en) | 2005-03-22 | 2006-03-22 | Delivery systems and methods for diagnosing and treating cardiovascular diseases |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1866416A2 (en) |
JP (1) | JP2008534508A (en) |
CN (1) | CN101189339A (en) |
AU (1) | AU2006227133A1 (en) |
CA (1) | CA2602946A1 (en) |
WO (1) | WO2006102395A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066978B2 (en) | 2010-05-26 | 2015-06-30 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0625523D0 (en) | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
EP1964571B1 (en) * | 2007-03-01 | 2012-05-02 | CSL Limited | Treatment of endothelial dysfunction in diabetic patients |
US7956035B2 (en) | 2007-03-01 | 2011-06-07 | Csl Limited | Treatment of endothelial dysfunction in diabetic patients |
WO2008124639A2 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Poly (amino acid) targeting moieties |
CN101688252A (en) * | 2007-07-11 | 2010-03-31 | 皇家飞利浦电子股份有限公司 | In vivo expression analysis using ultrasound-induced transfection of reporter constructs |
EP2019318A1 (en) * | 2007-07-27 | 2009-01-28 | Erasmus University Medical Center Rotterdam | Protein markers for cardiovascular events |
GB0811856D0 (en) | 2008-06-27 | 2008-07-30 | Ucl Business Plc | Magnetic microbubbles, methods of preparing them and their uses |
AU2010244431B2 (en) * | 2009-05-05 | 2015-05-14 | Lumito Ab | A system, method, and luminescent marker for improved diffuse luminescent imaging or tomography in scattering media |
AU2010254551B2 (en) | 2009-05-27 | 2016-10-20 | Selecta Biosciences, Inc. | Immunomodulatory agent-polymeric compounds |
JP5463549B2 (en) * | 2009-09-08 | 2014-04-09 | 学校法人福岡大学 | Liposomes for ultrasound therapy and liposomes for promoting ultrasound therapy |
WO2011133685A2 (en) * | 2010-04-21 | 2011-10-27 | President And Fellows Of Harvard College | Nanoparticle targeting to ischemia for imaging and therapy |
US20120021010A1 (en) * | 2010-04-29 | 2012-01-26 | University Of Calcutta | Antiplatelet agent and methods of using the same |
WO2012047584A2 (en) * | 2010-09-27 | 2012-04-12 | Janssen Biotech, Inc. | Macaca fascicularis ccl17 |
US20130028857A1 (en) | 2011-07-29 | 2013-01-31 | Selecta Biosciences, Inc. | Synthetic nanocarriers comprising polymers comprising multiple immunomodulatory agents |
CN102657875B (en) * | 2012-04-11 | 2013-09-04 | 中国人民解放军第三军医大学第二附属医院 | ANT1 gene-based targeted immunoliposome, preparation method thereof and application thereof |
CN103006538A (en) * | 2012-11-09 | 2013-04-03 | 叶琳 | Ultrasonic microbubbles for treating arthritis and use thereof |
US9693958B2 (en) | 2013-03-15 | 2017-07-04 | Cureport, Inc. | Methods and devices for preparation of lipid nanoparticles |
WO2014189306A1 (en) * | 2013-05-22 | 2014-11-27 | 메타볼랩(주) | Anti-tnf-α/cxcl10 double-targeting antibody and use thereof |
WO2015026884A1 (en) * | 2013-08-21 | 2015-02-26 | Boehringer Ingelheim International Gmbh | Cx3cr1-targeting imaging agents and their use in the diagnosis and treatment of disease |
CN105950660B (en) * | 2016-06-27 | 2019-11-01 | 姚陈 | Adenovirus vector and its application of one species specificity inhibition smooth muscle cell proliferation and migration |
CN106474487A (en) * | 2016-11-14 | 2017-03-08 | 中国人民解放军总医院 | A kind of targeting fluorescence medicament-carried nano molecular probe and its preparation method and application |
TW201829448A (en) | 2016-12-15 | 2018-08-16 | 大陸商深圳瑞健生命科學硏究院有限公司 | Method and drug for preventing and treating obesity |
EP3556387A4 (en) * | 2016-12-15 | 2020-09-09 | Talengen International Limited | Method for preventing and treating lipid metabolism disorders and related diseases thereof |
CA3047175A1 (en) * | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for mitigating heart disease |
WO2019215300A1 (en) | 2018-05-09 | 2019-11-14 | Medirista Biotechnologies Ab | Antibodies for use in combination therapy |
CN109061139A (en) * | 2018-06-19 | 2018-12-21 | 温州医科大学附属第医院 | Application of the serum inflammatory biomarker in prevention and treatment acute cerebral ischemic infarction |
CN114364383A (en) * | 2019-06-05 | 2022-04-15 | 微脉管治疗有限公司 | Compositions and methods for detecting and treating thrombosis and vascular plaque |
CN110201194A (en) * | 2019-07-23 | 2019-09-06 | 山东百多安医疗器械有限公司 | A kind of load medicine contrast microbubbles and preparation method thereof for treating atherosclerotic plaque |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992020701A2 (en) * | 1991-05-16 | 1992-11-26 | Miller D Douglas | Interleukin receptor targeted molecules for treatment of accelerated atherosclerosis |
WO1994025073A1 (en) * | 1993-04-30 | 1994-11-10 | Rhone-Poulenc Rorer S.A. | Recombinant viruses and their use in gene therapy |
WO1996027020A1 (en) * | 1995-03-02 | 1996-09-06 | Rhone-Poulenc Rorer S.A. | Atherosclerosis gene therapy using monocyte line hdl production |
US5632991A (en) * | 1988-11-14 | 1997-05-27 | Brigham & Women's Hospital | Antibodies specific for E-selectin and the uses thereof |
US5955584A (en) * | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
WO2000004926A2 (en) * | 1998-07-22 | 2000-02-03 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
WO2001010450A1 (en) * | 1999-08-10 | 2001-02-15 | Imarx Therapeutics, Inc. | Targeted thrombolytic agents |
WO2001032070A2 (en) * | 1999-10-26 | 2001-05-10 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
WO2002009649A2 (en) * | 2000-08-01 | 2002-02-07 | The University Of Kansas | Cell internalized peptide-drug conjugates |
US20020168370A1 (en) * | 1998-07-22 | 2002-11-14 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
WO2003092737A1 (en) * | 2002-04-30 | 2003-11-13 | Molmed Spa | Fusions of cytokines and tumor targeting proteins |
US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
WO2005058153A2 (en) * | 2003-12-19 | 2005-06-30 | Amersham Health As | Optical imaging contrast agents comprising a targeting vector linked to a fluorophore |
-
2006
- 2006-03-22 CN CNA2006800135939A patent/CN101189339A/en active Pending
- 2006-03-22 EP EP06739249A patent/EP1866416A2/en not_active Withdrawn
- 2006-03-22 CA CA002602946A patent/CA2602946A1/en not_active Abandoned
- 2006-03-22 WO PCT/US2006/010371 patent/WO2006102395A2/en active Application Filing
- 2006-03-22 AU AU2006227133A patent/AU2006227133A1/en not_active Abandoned
- 2006-03-22 JP JP2008503125A patent/JP2008534508A/en not_active Withdrawn
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955584A (en) * | 1986-03-31 | 1999-09-21 | Charter Ventures | Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof |
US5632991A (en) * | 1988-11-14 | 1997-05-27 | Brigham & Women's Hospital | Antibodies specific for E-selectin and the uses thereof |
WO1992020701A2 (en) * | 1991-05-16 | 1992-11-26 | Miller D Douglas | Interleukin receptor targeted molecules for treatment of accelerated atherosclerosis |
WO1994025073A1 (en) * | 1993-04-30 | 1994-11-10 | Rhone-Poulenc Rorer S.A. | Recombinant viruses and their use in gene therapy |
WO1996027020A1 (en) * | 1995-03-02 | 1996-09-06 | Rhone-Poulenc Rorer S.A. | Atherosclerosis gene therapy using monocyte line hdl production |
US20050019266A1 (en) * | 1997-05-06 | 2005-01-27 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
US20020168370A1 (en) * | 1998-07-22 | 2002-11-14 | Mcdonald John R. | Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
WO2000004926A2 (en) * | 1998-07-22 | 2000-02-03 | Osprey Pharmaceuticals Limited | Conjugates for treating inflammatory disorders and associated tissue damage |
WO2001010450A1 (en) * | 1999-08-10 | 2001-02-15 | Imarx Therapeutics, Inc. | Targeted thrombolytic agents |
WO2001032070A2 (en) * | 1999-10-26 | 2001-05-10 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
WO2002009649A2 (en) * | 2000-08-01 | 2002-02-07 | The University Of Kansas | Cell internalized peptide-drug conjugates |
WO2003092737A1 (en) * | 2002-04-30 | 2003-11-13 | Molmed Spa | Fusions of cytokines and tumor targeting proteins |
WO2005058153A2 (en) * | 2003-12-19 | 2005-06-30 | Amersham Health As | Optical imaging contrast agents comprising a targeting vector linked to a fluorophore |
Non-Patent Citations (6)
Title |
---|
BELIZAIRE A-K ET AL: "Identification of a murine ICAM-1-specific peptide by subtractive phage library selection on cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 309, no. 3, 26 September 2003 (2003-09-26), pages 625 - 630, XP004453645, ISSN: 0006-291X * |
DEMOS S M ET AL: "In vitro targeting of acoustically reflective immunoliposomes to fibrin under various flow conditions", JOURNAL OF DRUG TARGETING, vol. 5, no. 6, 1998, pages 507 - 518, XP008074992, ISSN: 1061-186X * |
DENEFLE P P ET AL: "TOWARDS GENE THERAPY TARGETING HDL", INTERNATIONAL CONGRESS SERIES, EXCERPTA MEDICA, AMSTERDAM, NL, October 1994 (1994-10-01), pages 501 - 505, XP000572778, ISSN: 0531-5131 * |
LUTTERS B C H ET AL: "Blocking endothelial adhesion molecules: A potential therapeutic strategy to combat atherogenesis", CURRENT OPINION IN LIPIDOLOGY, vol. 15, no. 5, 2004, pages 545 - 552, XP008074993, ISSN: 0957-9672 * |
VILLANUEVA ET AL: "Microbubbles targeted to intercellular adhesion molecule-1 bind to activated coronary artery endothelial cells", CIRCULATION, vol. 98, no. 1, 7 July 1998 (1998-07-07), pages 1 - 5, XP002092048, ISSN: 0009-7322 * |
WELLER GREGORY E R ET AL: "Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium.", ANNALS OF BIOMEDICAL ENGINEERING, vol. 30, no. 8, September 2002 (2002-09-01), pages 1012 - 1019, XP007901749, ISSN: 0090-6964 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066978B2 (en) | 2010-05-26 | 2015-06-30 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
Also Published As
Publication number | Publication date |
---|---|
EP1866416A2 (en) | 2007-12-19 |
CN101189339A (en) | 2008-05-28 |
AU2006227133A1 (en) | 2006-09-28 |
JP2008534508A (en) | 2008-08-28 |
WO2006102395A2 (en) | 2006-09-28 |
CA2602946A1 (en) | 2006-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006102395A3 (en) | Delivery systems and methods for diagnosing and treating cardiovascular diseases | |
WO2007033230A3 (en) | Anti-cd3 antibody formulations | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
WO2008070344A3 (en) | Compositions and methods for binding sphingosine-1-phosphate | |
WO2007115049A3 (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
UA102667C2 (en) | Human neutralizing anti b7rp1 antibody | |
WO2008116219A3 (en) | Uses of monoclonal antibody 8h9 | |
WO2007059203A3 (en) | Treating inflammatory disorders with antibodies to the alpha-7 nicotinic receptors | |
WO2006099875A8 (en) | Antibodies against cd38 for treatment of multiple myeloma | |
WO2007022520A3 (en) | Antibody-mediated enhancement of immune response | |
WO2009112245A9 (en) | Antibody against the csf-1 r | |
BRPI0611414B8 (en) | antibody or antigen-binding fragment thereof that binds to human tweak, pharmaceutical composition and its uses | |
WO2006044643A3 (en) | Anti-cd70 antibody and its use for the treatment and prevention of cancer and immune disorders | |
WO2006099698A3 (en) | Novel anti-plgf antibody | |
NZ595235A (en) | Compositions and methods for increasing muscle growth | |
TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
WO2006113909A3 (en) | Humanized anti-cd70 binding agents and uses thereof | |
WO2009083009A3 (en) | Monoclonal antibodies against cd32b | |
NO20071436L (en) | Humanized Anti-5T4 Antibodies and Anti-5T4 Antibody / Calicheamicin Conjugates | |
TW200642694A (en) | Anti-M-CSF antibody compositions | |
WO2006122257A3 (en) | Nebulization of monoclonal antibodies for treating pulmonary diseases | |
EP2684889A3 (en) | Multivariable antigens complexed with targeting humanized monoclonal antibody | |
WO2010066803A3 (en) | Human antibodies against human tissue factor | |
WO2019215510A8 (en) | Compositions and methods related to anti-cd19 antibody drug conjugates | |
WO2005100405A3 (en) | Phosphorylcholine conjugates and corresponding antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680013593.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2602946 Country of ref document: CA Ref document number: 2008503125 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006227133 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006739249 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4051/KOLNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006227133 Country of ref document: AU Date of ref document: 20060322 Kind code of ref document: A |